Fenofibrate
- Generic Name
- Fenofibrate
- Brand Names
- Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21ClO4
- CAS Number
- 49562-28-9
- Unique Ingredient Identifier
- U202363UOS
- Background
Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.
Fenofibrate was granted FDA approval on 31 December 1993.
- Indication
Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.
- Associated Conditions
- Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
- Associated Therapies
- -
Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Yokohama City University
- Target Recruit Count
- 360
- Registration Number
- NCT06623539
- Locations
- 🇯🇵
Yokohama city university, Yokohama, Kanagawa, Japan
A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis
- Conditions
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Han Ying
- Target Recruit Count
- 30
- Registration Number
- NCT06591455
Role of Fenofibrate in Neonatal Jaundice
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 75
- Registration Number
- NCT06451900
- Locations
- 🇪🇬
Ain Shams University Hospitals, Cairo, Abbassia, Egypt
Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 117
- Registration Number
- NCT06365424
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China
Comparison of Effects of Fenofibrate Adjuvant Therapy Versus Conventional Phototherapy in Neonatal Jaundice.
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Muhammad Zark
- Target Recruit Count
- 156
- Registration Number
- NCT06346743
- Locations
- 🇵🇰
Services Institute of Medical Sciences, Lahore, Punjab, Pakistan
Fenofibrate in Patients with Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Lindsay Ferguson, MD
- Target Recruit Count
- 24
- Registration Number
- NCT06191133
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
- Conditions
- Interventions
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Han Ying
- Target Recruit Count
- 184
- Registration Number
- NCT06174402
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China
Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 44
- Registration Number
- NCT06155331
- Locations
- 🇪🇬
Hagar Dewidar, Tanta, Elgharbya, Egypt
Safety Study of Fenofibrate During Pregnancy
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- First People's Hospital of Hangzhou
- Target Recruit Count
- 250
- Registration Number
- NCT05883865
- Locations
- 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT05781698
- Locations
- 🇪🇬
Faculty of Medicine, Menoufia University, Tanta, Shebeen El-Kom, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.